ONCS ends the year on a high note, gains of 40% in the last month.
What many people may not realize is that ONCS has had a tremendous year, gains of 75%. While most biotech investors are used to breakout 200%+ performances for select biotechs, I prefer ONCS' pace. The stock is trending higher in a slow-and-steady manner, which prevents sudden downtrends and also indicates buy-and-hold investors.
With more data ahead, 2014 could be another year like 2013. Definitely holding this stock